☰

Mitsi A. Blount, Ph.D. - Publications

Affiliations: 
2006 Vanderbilt University, Nashville, TN 
Area:
Biochemistry
Tree Info Similar researchers PubMed Report error

18 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Himmel NJ, Rogers RT, Redd SK, Wang Y, Blount MA. Purinergic signaling is enhanced in the absence of UT-A1 and UT-A3. Physiological Reports. 9: e14636. PMID 33369887 DOI: 10.14814/phy2.14636  0.67
2018 Himmel NJ, Wang Y, Rodriguez DA, Sun MA, Blount MA. Chronic lithium treatment induces novel patterns of pendrin localization and expression. American Journal of Physiology. Renal Physiology. PMID 29667915 DOI: 10.1152/Ajprenal.00065.2018  0.66
2014 Sim JH, Himmel NJ, Redd SK, Pulous FE, Rogers RT, Black LN, Hong SM, von Bergen TN, Blount MA. Absence of PKC-alpha attenuates lithium-induced nephrogenic diabetes insipidus. Plos One. 9: e101753. PMID 25006961 DOI: 10.1371/Journal.Pone.0101753  0.676
2011 Francis SH, Blount MA, Corbin JD. Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiological Reviews. 91: 651-90. PMID 21527734 DOI: 10.1152/Physrev.00030.2010  0.553
2011 Corbin JD, Foster TL, Bessay E, Busch J, Blount M, Francis SH. Metal ion stimulators of PDE5 cause similar conformational changes in the enzyme as does cGMP or sildenafil. Cellular Signalling. 23: 778-84. PMID 21187142 DOI: 10.1016/J.Cellsig.2010.12.005  0.694
2008 Bessay EP, Blount MA, Zoraghi R, Beasley A, Grimes KA, Francis SH, Corbin JD. Phosphorylation increases affinity of the phosphodiesterase-5 catalytic site for tadalafil. The Journal of Pharmacology and Experimental Therapeutics. 325: 62-8. PMID 18199808 DOI: 10.1124/Jpet.107.133405  0.624
2007 Blount MA, Zoraghi R, Bessay EP, Beasley A, Francis SH, Corbin JD. Conversion of phosphodiesterase-5 (PDE5) catalytic site to higher affinity by PDE5 inhibitors. The Journal of Pharmacology and Experimental Therapeutics. 323: 730-7. PMID 17690252 DOI: 10.1124/Jpet.107.126540  0.655
2007 Bessay EP, Zoraghi R, Blount MA, Grimes KA, Beasley A, Francis SH, Corbin JD. Phosphorylation of phosphodiesterase-5 is promoted by a conformational change induced by sildenafil, vardenafil, or tadalafil. Frontiers in Bioscience : a Journal and Virtual Library. 12: 1899-910. PMID 17127429 DOI: 10.2741/2196  0.61
2007 Corbin J, Bessay EP, Blount MA, Zoraghi R, Morris GZ, Weeks JL, Ke H, Francis SH. Negative feedback control of the nitric oxide/cGMP pathway in smooth muscle Bmc Pharmacology. 7. DOI: 10.1186/1471-2210-7-S1-S30  0.716
2006 Blount MA, Zoraghi R, Ke H, Bessay EP, Corbin JD, Francis SH. A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization. Molecular Pharmacology. 70: 1822-31. PMID 16926278 DOI: 10.1124/Mol.106.028688  0.563
2005 Corbin JD, Beasley A, Blount MA, Francis SH. High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors. Biochemical and Biophysical Research Communications. 334: 930-8. PMID 16023993 DOI: 10.1016/J.Bbrc.2005.06.183  0.56
2005 Weeks JL, Blount MA, Beasley A, Zoraghi R, Thomas MK, Sekhar KR, Corbin JD, Francis SH. Radiolabeled ligand binding to the catalytic or allosteric sites of PDE5 and PDE11. Methods in Molecular Biology (Clifton, N.J.). 307: 239-62. PMID 15988068 DOI: 10.1385/1-59259-839-0:239  0.72
2005 Francis SH, Blount MA, Zoraghi R, Corbin JD. Molecular properties of mammalian proteins that interact with cGMP: protein kinases, cation channels, phosphodiesterases, and multi-drug anion transporters. Frontiers in Bioscience : a Journal and Virtual Library. 10: 2097-117. PMID 15970481 DOI: 10.2741/1684  0.612
2004 Corbin JD, Beasley A, Blount MA, Francis SH. Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5). Neurochemistry International. 45: 859-63. PMID 15312980 DOI: 10.1016/J.Neuint.2004.03.016  0.556
2004 Blount MA, Beasley A, Zoraghi R, Sekhar KR, Bessay EP, Francis SH, Corbin JD. Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Molecular Pharmacology. 66: 144-52. PMID 15213306 DOI: 10.1124/Mol.66.1.144  0.631
2004 Kotera J, Francis SH, Grimes KA, Rouse A, Blount MA, Corbin JD. Allosteric sites of phosphodiesterase-5 sequester cyclic GMP. Frontiers in Bioscience : a Journal and Virtual Library. 9: 378-86. PMID 14766375 DOI: 10.2741/1231  0.592
2003 Corbin JD, Blount MA, Weeks JL, Beasley A, Kuhn KP, Ho YS, Saidi LF, Hurley JH, Kotera J, Francis SH. [3H]sildenafil binding to phosphodiesterase-5 is specific, kinetically heterogeneous, and stimulated by cGMP. Molecular Pharmacology. 63: 1364-72. PMID 12761347 DOI: 10.1124/Mol.63.6.1364  0.716
2003 Weeks JL, Blount MA, Beasley A, Kotera J, Ho YS, Kuhn KP, Saidi LF, Hurley JH, Francis SH, Corbin JD. New features of PDE5 as revealed by a potent catalytic-site specific radioligand Bmc News and Views. 3. DOI: 10.1186/2048-4623-3-s2-p0054  0.676
Show low-probability matches.